Navigation Links
Colorectal cancer patients with gene mutation show better response to cancer agent
Date:10/26/2010

Even though the cancer-treatment agent cetuximab is not considered effective treatment for KRAS (a gene)-mutated metastatic colorectal tumors, new research indicates that patients with colorectal cancer not responding to chemotherapy and a certain variation of this gene who were treated with cetuximab had longer overall and progression-free survival than patients with other KRAS-mutations, according to a study in the October 27 issue of JAMA.

"Recent retrospective correlative analyses of metastatic colorectal cancer trials indicate that patients with KRAS-mutated tumors do not benefit from the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab and panitumumab," the authors write. However, they add there are indications that not all KRAS mutations are equal in their biological characteristics, including anecdotal reports indicating that a minority of patients with KRAS-mutated tumors can respond to anti-EGFR therapy.

Wendy De Roock, M.D., of the University of Leuven, Leuven, Belgium, and colleagues conducted a study to examine whether a certain KRAS mutation (p.G13D) may be associated with a better outcome after cetuximab treatment than observed with other KRAS mutations. The study included a pooled data set of 579 patients with chemotherapy-refractory (not responsive to treatment) colorectal cancer treated with cetuximab between 2001 and 2008 and who were included in other clinical trials or received off-study treatment. Various analyses of the data were performed. The main efficacy outcome measure was overall survival; secondary efficacy measures were response rate and progression-free survival.

The researchers found that among patients who received any cetuximab-based treatment (cetuximab monotherapy or cetuximab plus chemotherapy) (n = 571), overall and progression-free survival were significantly longer in patients with p.G13D-mutated tumors (overall survival: n=32; median [midpoint], 7.6 months;
'/>"/>

Contact: Sabine Tejpar, M.D., Ph.D.
sabine.tejpar@uzleuven.be
JAMA and Archives Journals
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Colorectal cancer screening can be expanded by offering it during mammography visits
2. Virtual colonoscopy option could improve colorectal cancer screening rates, patient survey suggests
3. Virtual colonoscopy and teleradiology bring colorectal cancer screening to patients in rural areas
4. Type 2 diabetes and insulin use are associated with colorectal cancer in men
5. Notable racial disparities in diagnosis, treatment and outcomes of colorectal cancer
6. Lack of insurance coverage remains obstacle to wider colorectal cancer screening with CT colonography
7. Colorectal cancer screening in Canada is cost-effective
8. Could Hot Weather Affect Results of a Colorectal Cancer Test?
9. Smoking-related colorectal cancer in older women is associated with molecularly defined DNA changes
10. Smoking-related colorectal cancer in older women is associated with molecularly-defined DNA changes
11. Hydrophobic proteins: Potential biomarkers for colorectal cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... (PRWEB) March 29, 2015 The ... ( http://www.testosteronelawsuithub.com/ ) pending in the U.S. District ... litigation’s next Case Management Conference for April 21st ... meeting will address the progress of product liability ... experienced heart attacks, strokes and other cardiovascular complications ...
(Date:3/29/2015)... March 29, 2015 At this ... platform provides basic health information around medical conditions ... discuss these challenges as well as helping them ... addresses six medical conditions using evidenced based information ... engage in conversations around them., ...
(Date:3/29/2015)... Ore. (PRWEB) March 29, 2015 Youth ... Marion counties in Oregon to assess the feasibility of ... with emotional and behavioral problems and their families. , ... to select participants that will be provided technical assistance ... Oregon counties join six other national awardees chosen by ...
(Date:3/29/2015)... 29, 2015 Final Cut Pro ... from Pixel Film Studios, entitled TranSports. , “TranSports ... for Final Cut Pro X,” said Christiana Austin, CEO ... tools needed to effortlessly transition using this cool sports ... new and uniquely styled transition pack for Final Cut ...
(Date:3/29/2015)... TN (PRWEB) March 29, 2015 North ... several PT Online Continuing Education Courses . ... 10.0 hours of CME - TPTA, approval # 56399TX ... the evaluation of the shoulder complex - 10.5 hours ... Approved #56400TX , Examination and Treatment of the SI ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 2Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 3Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2
... Findings of a recent study suggests hunger may be ... researchers // studied 16 men who agreed to skip breakfast. ... evening. Participants were asked to consume sugary, salty or bitter ... not swallow the drinks, but instead spit them out after ...
... with chemo-resistant leukemia, a new drug is showing promising ... experimenting with bacteria-based recombinant immunotoxins. An immunotoxin is bioengineered ... part of the antibodies that are commonly used to ... encouraging results in a phase II study. ,Researchers ...
... Latest research shows the chickenpox vaccine loses some ... vaccination.// Parents are encouraged to vaccinate their children ... Consequently, researchers were prompted to further investigate the ... individuals. ,Researchers studied nearly 350 children ...
... common form of cancer in the United States. According to ... against colon cancer. In addition, soy protein may help minimize ... fed five different diets to female mice and followed their ... the effects of specific ingredients. Diet one contained milk protein, ...
... get up and get moving. Breast cancer survivors ... body esteem and better mood than sedentary breast ... ,Researchers compared 40 women who said they regularly ... cancer survivors. Regular exercisers reported significantly more positive ...
... depression may have an increased risk of heart disease ... than 93,600 older women who participated in the Women's ... long-term program designed to determine how biological and lifestyle ... and other health conditions. For this study, participants were ...
Cached Medicine News:
(Date:3/29/2015)...  Three-month paliperidone palmitate, an investigational atypical antipsychotic, ... in patients with schizophrenia, according to a new ... the Journal of the American Medical ... of the study served as the basis for ... three-month paliperidone palmitate injection to treat schizophrenia in ...
(Date:3/27/2015)... 27, 2015 BioCorRx, Inc. ( ... California is a healthcare solutions organization, which focuses ... at $22 billion in the U.S. alone. The Company created ... Naltrexone in a specially compounded form for outpatient surgical implantation. ... and New Zealand ) to the ...
(Date:3/27/2015)... 2015 Across the global healthcare landscape, the ... clinical development, market education, and regulatory compliance. As emerging ... function is expected to increase in prominence and follow ... According to research by benchmarking firm, Best Practices, LLC, ... to Medical Affairs. Among companies in India ...
Breaking Medicine Technology:New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Medical Affairs Capabilities Expanding in Emerging Marketplaces 2
... Aug. 16 Endologix, Inc. (Nasdaq: ELGX ... announced today that it has entered into a development ... for its balloon expandable stent technology. Evasc is a ... patented stent is made from cobalt chromium and is ...
... PRA International, a leading Clinical Research Organization, will host ... drug development on 24 August 2010 at 11:30 am ... PRA,s Scientific Affairs unit, will be the presenter. ... of the expensive failures that pharmaceutical companies experience during ...
Cached Medicine Technology:Endologix Enters Development Agreement and Exclusive License for Balloon Expandable Stent Technology 2Endologix Enters Development Agreement and Exclusive License for Balloon Expandable Stent Technology 3PRA International Hosts Audio Conference on CV Drug Development 2
Blood sedimentation rate analysis...
Blood sedimentation rate analysis...
The Sedimat 15 Automated sedrate system provides an accurate ESR result in only 15 minutes. Fast, in-office results (before patient leaves the office) can lead to improved patient therapy....
The CA-500 series quickly and accurately measures up to 5 coagulation parameters. It is the analyzer of choice for low to mid volume laboratories, or as a backup to larger coagulation analyzers....
Medicine Products: